AI Pathology
Tempus Digital Pathology alternatives
13 tools that we compared head to head with Tempus Digital Pathology in a written verdict. Each row says who the tool suits, according to that verdict, and links to the full comparison.
The list is not a ranking. Tools in the same category come first, then every group is in alphabetical order. A tool that is no longer sold is left out.
aetherAI
Cleared viewer for primary diagnosis, K233126; cleared with Philips scanner and monitor
See the review for plans
Full comparison
Aiforia
Clinical suites for breast, lung, colon and gastric; aiforia Create for building in-house models
See the review for plans
Full comparison
Artera
Ten-year metastasis risk for prostate cancer, males 55 or older; de Novo DEN240068, July 2025
See the review for plans
Full comparison
Caris Life Sciences
Tissue profiling plus blood tests such as Caris Assure; companion-diagnostic indications include BRAF V600E and V600K melanoma
See the review for plans
Full comparison
Freenome
PMA-approved, P250029, July 2026; freenome says PREEMPT CRC enrolled 48,000+ adults
See the review for plans
Full comparison
GRAIL
Breakthrough Device designation, 2018; pMA submitted in full January 2026
See the review for plans
Full comparison
Ibex Medical Analytics
Prostate 510(k) K241232, January 2025; cE marked on several solutions, IVDR for prostate
See the review for plans
Full comparison
Indica Labs HALO AI
HALO AP Dx cleared, latest K252762 in November 2025; train-by-example classifiers for brightfield and fluorescence
See the review for plans
Full comparison
PathAI AISight
FDA-cleared AISight Dx for FFPE primary diagnosis; cleared on Hamamatsu S360MD and Leica GT 450 DX
See the review for plans
Full comparison
Proscia Concentriq
Two 510(k) records for Concentriq AP-Dx; sOC 2 Type II announced December 2025
See the review for plans
Full comparisonSectra Pathology
IDS7 worklists, reporting and image review; digital Pathology Module, 510(k) March 2020 and April 2024
See the review for plans
Full comparison
Vesta
BCG response and recurrence risk scoring for bladder cancer; report ordered by the treating urologist
See the review for plans
Full comparison
Visiopharm
Vendor-stated IVDR apps for breast, lung and prostate; 2025 HER2-low agreement study
See the review for plans
Full comparison